Study of Afatinib in Advanced Cutaneous Squamous Cell Carcinoma

NCT05070403 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

25

Enrollment

OTHER

Sponsor class

Conditions

Squamous Cell Carcinoma

Interventions

DRUG: Afatinib 40 MG

Sponsor

H. Lee Moffitt Cancer Center and Research Institute

Collaborators

[object Object]